Management of Obstructive Sleep Apnea in Pregnancy
Screen all pregnant women for OSA using either a pregnancy-specific questionnaire or standard screening tool (such as STOP-Bang), and treat diagnosed cases with auto-titrating positive airway pressure (auto-PAP) as first-line therapy, particularly for those with AHI ≥15 or AHI 5-15 with symptoms or comorbidities. 1
Screening Approach
The 2026 American College of Chest Physicians guideline specifically addresses OSA in pregnancy and recommends universal screening 1. This is critical because:
- Pregnancy physiologically increases OSA risk through weight gain, airway edema, reduced functional residual capacity, and hormonal changes 2, 3
- OSA symptoms (snoring, gasping) are often dismissed as normal pregnancy changes, leading to underdiagnosis 4
- The condition carries significant maternal-fetal morbidity if untreated
High-risk populations requiring screening include:
- Overweight/obese pregnant women
- Those with gestational hypertension or preeclampsia
- Women with gestational diabetes
- Those reporting excessive daytime sleepiness, witnessed apneas, or habitual snoring
- Pregnant women with chronic hypertension or cardiovascular disease 1, 4
Diagnostic Testing
For pregnant women screening positive, proceed with either home sleep apnea testing (HSAT) or in-laboratory polysomnography (PSG) for diagnosis 1. The choice depends on:
- HSAT is appropriate for: Suspected moderate-to-severe uncomplicated OSA in pregnancy
- PSG is preferred for: Complex cases, suspected comorbid sleep disorders, or when HSAT results are inconclusive
This represents pregnancy-specific guidance, as the general adult OSA guidelines 5 don't address the unique urgency and physiological context of pregnancy.
Treatment Indications and Modality
Treatment thresholds in pregnancy:
- AHI ≥15: Treat regardless of symptoms or comorbidities
- AHI 5-15: Treat if symptoms (excessive daytime sleepiness, sleep fragmentation) OR sequelae/comorbidities present (hypertension, gestational diabetes, preeclampsia risk) 1
Auto-titrating PAP (auto-PAP/APAP) is the preferred initial therapy 1. This differs slightly from general adult guidelines that recommend CPAP as default 5, but auto-PAP offers advantages in pregnancy:
- Accommodates physiological changes throughout gestation
- Better tolerability may improve adherence
- Equivalent efficacy to fixed CPAP 5
Evidence for PAP Therapy Benefits
Recent meta-analysis data (2026) demonstrates that PAP therapy in high-risk pregnant women with OSA:
- Significantly reduces fasting plasma glucose (mean difference -6.50 mg/dL)
- Improves insulin resistance (reduced HOMA-IR by 0.90)
- Shows trends toward improved maternal-fetal outcomes, though effects on hypertensive disorders, cesarean rates, and neonatal outcomes remain limited 6
Critical caveat: Adherence to CPAP/PAP therapy is often suboptimal in pregnancy 2. Address this through:
- Early education about maternal-fetal risks of untreated OSA
- Scheduled follow-up at 1 week, 1 month, and throughout pregnancy
- Consideration of scheduled naps as adjunctive therapy for residual symptoms 1
Alternative Therapies
Mandibular advancement devices (MADs) may be considered for:
- Mild OSA (AHI 5-15) without significant comorbidities
- PAP intolerance or refusal
- However, evidence in pregnancy is limited 5, 3
Weight loss interventions are generally not recommended during pregnancy, contrasting with the strong recommendation for weight loss in non-pregnant adults with OSA 5. Focus instead on:
- Sleep hygiene
- Positional therapy for position-dependent OSA
- Avoidance of alcohol and sedative medications
Maternal-Fetal Risks of Untreated OSA
Understanding these risks justifies aggressive screening and treatment:
Maternal complications:
- Gestational hypertension and preeclampsia
- Gestational diabetes mellitus
- Cardiomyopathy
- Higher cesarean delivery rates
- Depression 2, 4, 3
Fetal/neonatal complications:
- Intrauterine growth restriction (IUGR)
- Preterm birth
- Low birth weight
- Perinatal mortality
- NICU admission 2, 4, 3
The pathophysiology involves increased sympathetic activity, intermittent hypoxemia, immune dysfunction, and systemic inflammation 4.
Postpartum Reassessment
Reassess OSA in the postpartum period for select patients 1. This is important because:
- Some pregnancy-related OSA resolves with weight loss and hormonal normalization
- However, many women remain at risk, particularly those with obesity or persistent symptoms
- Postpartum reassessment guides long-term management decisions
Indications for postpartum follow-up:
- Moderate-to-severe OSA diagnosed during pregnancy
- Persistent symptoms postpartum
- Ongoing obesity or weight retention
- Development of chronic hypertension or metabolic complications
Common Pitfalls to Avoid
- Dismissing snoring/gasping as "normal pregnancy symptoms" - These warrant formal screening 4
- Delaying treatment pending postpartum period - Untreated OSA carries immediate maternal-fetal risks 2
- Using screening questionnaires alone for diagnosis - Objective sleep testing (HSAT or PSG) is required 1
- Inadequate adherence support - PAP therapy only works if used consistently; implement structured follow-up 2
- Failing to screen high-risk populations - Universal screening is recommended, but particularly critical for obese women and those with hypertensive/metabolic complications 1
The 2026 CHEST guideline 1 represents the most comprehensive, pregnancy-specific evidence synthesis available and should guide clinical decision-making, supplemented by general OSA management principles from established adult guidelines 5 where pregnancy-specific data are limited.